Verici Dx launches £8m share placing at 0.2p per share

Verici Dx proposed a placing of 4 billion new shares at 0.2 pence each to raise approximately £8 million gross (£7.4 million net); the shares represent about 175% of existing share capital and are priced at an 11.1% discount to the September 30 close. A separate retail offer aims to raise up to £250,000, while 2.32 billion placing shares require shareholder approval at an October 27 meeting. Proceeds are intended for commercial expansion, marketing, targeted capital expenditure and working capital; the company expects Tutivia revenue of $4.75 million for 2026.

Analysis

The key issue is the enlarged equity base, not the headline discount: if the full placing completes, the new shares equal roughly 175% of the pre-raise count, leaving existing holders with about 36% of the enlarged company before any retail shares. The prior close is a stale anchor after the trading suspension; the 11% discount is not evidence the reopening price is attractive. Expect technical supply and wider spreads when trading resumes, with the conditional tranche and shareholder vote extending uncertainty into late October.

The proceeds fund commercialization rather than remove the need to prove it. The stated Tutivia revenue expectation should be treated as company guidance, not validated demand: adoption, reimbursement, repeat ordering and sales productivity are the metrics that determine whether expanded commercial spending earns an adequate return. Failure to convert spending into revenue would make the dilution permanent without establishing a durable growth multiple. Conversely, credible subsequent sales evidence could turn the financing into a runway catalyst.

Near term, liquidity and price discovery dominate; over 1–3 months, approval, admission of conditional shares and any revenue updates matter most. Over 6–18 months, commercial execution is the thesis. The contrarian risk to a bearish read is that the raise may reduce near-term funding pressure, so avoid assuming distress or shorting into illiquid reopening conditions. No material read-through to Oberon Investments Group (OBE) can be established from its broker role alone.

Key Decisions for Investors

• VRCI: Do not trade through the suspension; reassess only after reopening, with live volume, spread and enlarged-share-count pricing. For existing exposure, consider reducing rather than averaging down if the market fails to absorb supply.
• Treat the October 27 approval and subsequent admission of conditional shares as near-term catalysts; verify completion, final share count and any restrictions on resale before sizing a position.
• Watch for evidence against the commercialization thesis: reported Tutivia revenue versus company guidance, reimbursement/adoption indicators, and whether commercial spending translates into repeat orders. Weak conversion would support continued underweight; credible execution would invalidate the simple dilution-bear case.
• OBE: no position based solely on its joint-broker appointment; any fee contribution is unquantified and should be verified in company disclosures before assigning earnings impact.